Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide since it was confirmed as the causative agent of COVID-19. Molecular diagnosis of the disease is typically performed via nucleic acid-based detection of the virus from swabs, sputum or bronchoalveolar lavage fluid (BALF). However, the positive rate from the commonly used specimens (swabs or sputum) was less than 75%. Immunological assays for SARS-CoV-2 are needed to accurately diagnose COVID-19. Sera were collected from patients or healthy people in a local hospital in Xiangyang, Hubei Province, China. The SARS-CoV-2 specific IgM antibodies were then detected using a SARS-CoV-2 IgM colloidal gold immunochromatographic assay (GICA). Results were analysed in combination with sera collection date and clinical information. The GICA was found to be positive with the detected 82.2% (37/45) of RT-qPCR confirmed COVID-19 cases, as well as 32.0% (8/25) of clinically confirmed, RT-qPCR negative patients (4-14 days after symptom onset). Investigation of IgM-negative, RT-qPCR-positive COVID-19 patients showed that half of them developed severe disease. The GICA was found to be a useful test to complement existing PCR-based assays for confirmation of COVID-19, and a delayed specific IgM antibody response was observed among COVID-19 patients with severe progression

Year of Publication: 2020
Contained in: Emerging microbes & infections Vol. 9, No. 1 (2020), p. 1096-1101
All journal articles: Search for all articles in this journal
Language: English
Contributors: Shen, Liang | Author
Wang, Chunhua
Zhao, Jianzhong
Tang, Xiaoyong
Shen, Ying
Lu, Mingqing
Ding, Zhe
Huang, Canping
Zhang, Ji
Li, Shichao
Lan, Jiaming
Wong, Gary
Zhu, Yufang
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: COVID-19
GICA
IgM antibody
Journal Article
delayed
severity
Additional Keywords: *Antibody Formation
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Viral
Betacoronavirus
Child
China
Clinical Laboratory Techniques
Coronavirus Infections
Disease Progression
Female
Humans
Immunoassay
Immunoglobulin M
Male
Middle Aged
Pandemics
Pneumonia, Viral
Real-Time Polymerase Chain Reaction
Young Adult
ISSN: 2222-1751
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 02.06.2020
Date Revised 02.06.2020
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32476607
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1080/22221751.2020.1766382
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 04413nma a2200949 c 4500
001 NLM311461751
003 DE-601
005 20200603213822.0
007 cr uuu---uuuuu
008 200601s2020 000 0 eng d
024 7 |a 10.1080/22221751.2020.1766382  |2 doi 
028 5 2 |a pubmed20n1220.xml 
035 |a (DE-599)NLM32476607 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Shen, Liang 
245 1 0 |a Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 02.06.2020 
500 |a Date Revised 02.06.2020 
500 |a published: Print 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide since it was confirmed as the causative agent of COVID-19. Molecular diagnosis of the disease is typically performed via nucleic acid-based detection of the virus from swabs, sputum or bronchoalveolar lavage fluid (BALF). However, the positive rate from the commonly used specimens (swabs or sputum) was less than 75%. Immunological assays for SARS-CoV-2 are needed to accurately diagnose COVID-19. Sera were collected from patients or healthy people in a local hospital in Xiangyang, Hubei Province, China. The SARS-CoV-2 specific IgM antibodies were then detected using a SARS-CoV-2 IgM colloidal gold immunochromatographic assay (GICA). Results were analysed in combination with sera collection date and clinical information. The GICA was found to be positive with the detected 82.2% (37/45) of RT-qPCR confirmed COVID-19 cases, as well as 32.0% (8/25) of clinically confirmed, RT-qPCR negative patients (4-14 days after symptom onset). Investigation of IgM-negative, RT-qPCR-positive COVID-19 patients showed that half of them developed severe disease. The GICA was found to be a useful test to complement existing PCR-based assays for confirmation of COVID-19, and a delayed specific IgM antibody response was observed among COVID-19 patients with severe progression 
611 2 7 |a Journal Article  |2 gnd 
653 2 |a Adolescent  |6 D000293 
653 2 |a Adult  |6 D000328 
653 2 |a Aged  |6 D000368 
653 2 |a Aged, 80 and over  |6 D000369 
653 2 |a Antibodies, Viral  |6 D000914  |a *blood  |6 Q000097  |a immunology  |6 Q000276 
653 2 |a *Antibody Formation  |6 D000917 
653 2 |a Betacoronavirus  |6 D000073640 
653 2 |a Child  |6 D002648 
653 2 |a China  |6 D002681 
653 2 |a Clinical Laboratory Techniques  |6 D019411 
653 2 |a Coronavirus Infections  |6 D018352  |a *diagnosis  |6 Q000175  |a *immunology  |6 Q000276 
653 2 |a Disease Progression  |6 D018450 
653 2 |a Female  |6 D005260 
653 2 |a Humans  |6 D006801 
653 2 |a Immunoassay  |6 D007118 
653 2 |a Immunoglobulin M  |6 D007075  |a *blood  |6 Q000097  |a immunology  |6 Q000276 
653 2 |a Male  |6 D008297 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a *diagnosis  |6 Q000175  |a *immunology  |6 Q000276 
653 2 |a Real-Time Polymerase Chain Reaction  |6 D060888 
653 2 |a Young Adult  |6 D055815 
655 7 |a COVID-19  |2 gnd 
655 7 |a GICA  |2 gnd 
655 7 |a IgM antibody  |2 gnd 
655 7 |a delayed  |2 gnd 
655 7 |a severity  |2 gnd 
655 7 |a Antibodies, Viral  |2 gnd 
655 7 |a Immunoglobulin M  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a COVID-19 
689 1 1 |a GICA 
689 1 2 |a IgM antibody 
689 1 3 |a delayed 
689 1 4 |a severity 
689 1 |5 DE-601 
689 2 0 |a Antibodies, Viral 
689 2 1 |a Immunoglobulin M 
689 2 |5 DE-601 
700 1 |a Wang, Chunhua 
700 1 |a Zhao, Jianzhong 
700 1 |a Tang, Xiaoyong 
700 1 |a Shen, Ying 
700 1 |a Lu, Mingqing 
700 1 |a Ding, Zhe 
700 1 |a Huang, Canping 
700 1 |a Zhang, Ji 
700 1 |a Li, Shichao 
700 1 |a Lan, Jiaming 
700 1 |a Wong, Gary 
700 1 |a Zhu, Yufang 
773 0 8 |i in  |t Emerging microbes & infections  |g Vol. 9, No. 1 (2020), p. 1096-1101  |q 9:1<1096-1101  |w (DE-601)NLM249572478  |x 2222-1751 
856 4 1 |u http://dx.doi.org/10.1080/22221751.2020.1766382  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 9  |j 2020  |e 1  |b 31  |c 12  |h 1096-1101